Based on the Merck & Company Inc stock forecast from 0 analysts, the average analyst target price for Merck & Company Inc is not available over the next 12 months. Merck & Company Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Merck & Company Inc is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Merck & Company Inc’s stock price was EUR 136.80. Merck & Company Inc’s stock price has changed by -3.73% over the past week, -0.91% over the past month and -2.81% over the last year.
No recent analyst target price found for Merck & Company Inc
No recent average analyst rating found for Merck & Company Inc
Company Overview Merck & Company Inc
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA. Read Less
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as w...Read More
Frequently Asked Questions About Merck & Company Inc (MRK:F) Stock
Stock Target Advisor's fundamental analysis for Merck & Company Inc's stock is Slightly Bearish.
MRK:F stock's dividend yield is 1.50%.
Our analysis grades MRK:F stock's dividend yield at F. This means that MRK:F stock's dividend yield is above 22% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this MRK:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on MRK:F's stock to indicate what its average analyst target is.
MRK:F stock's Price/Earning ratio is 22.92.
Our analysis grades MRK:F stock's Price / Earning ratio at F. This means that MRK:F stock's Price/Earning ratio is above 62% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this MRK:F may be a overvalued for its sector.
The last closing price of MRK:F's stock was EUR 136.80.
The most recent market capitalization for MRK:F is EUR 61.37B.
Unfortunately we do not have enough analyst data on MRK:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Merck & Company Inc's stock.
As per our most recent records Merck & Company Inc has 62,176 Employees.
Merck & Company Inc's registered address is Frankfurter Strasse 250, Darmstadt, Germany, 64293.
You can get more information about it from Merck & Company Inc's website at https://www.merckgroup.com/en.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Merck & Company Inc (MRK:F) Stock
Stock Target Advisor's fundamental analysis for Merck & Company Inc's stock is Slightly Bearish.
MRK:F stock's dividend yield is 1.50%.
Our analysis grades MRK:F stock's dividend yield at F. This means that MRK:F stock's dividend yield is above 22% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this MRK:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on MRK:F's stock to indicate what its average analyst target is.
MRK:F stock's Price/Earning ratio is 22.92.
Our analysis grades MRK:F stock's Price / Earning ratio at F. This means that MRK:F stock's Price/Earning ratio is above 62% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this MRK:F may be a overvalued for its sector.
The last closing price of MRK:F's stock was EUR 136.80.
The most recent market capitalization for MRK:F is EUR 61.37B.
Unfortunately we do not have enough analyst data on MRK:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Merck & Company Inc's stock.
As per our most recent records Merck & Company Inc has 62,176 Employees.
Merck & Company Inc's registered address is Frankfurter Strasse 250, Darmstadt, Germany, 64293.
You can get more information about it from Merck & Company Inc's website at https://www.merckgroup.com/en.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MRK:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
